Search results: Sage Journals

Restricted accessOtherFirst published August, 2011

EMA Approves Revision of Label for Tysabri

Biotechnology Law Report

Restricted accessResearch articleFirst published February, 2011

An approach to natalizumab hypersensitivity: a case series of induction of tolerance

Marie Camacho-Halili, Roxanne George, Malcolm Gottesman [...]

Multiple Sclerosis Journal

Restricted accessResearch articleFirst published April, 2021

Real-world disability improvement in patients with relapsing–remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program

Heinz Wiendl, Tim Spelman, Helmut Butzkueven [...]

Multiple Sclerosis Journal

Restricted accessResearch articleFirst published March, 2021

Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri ® Observational Program (TOP)

Helmut Butzkueven, Maria Trojano, Ludwig Kappos [...]

Multiple Sclerosis Journal

Restricted accessOtherFirst published October, 2009

Medicare Taking Close Look at Erythropoietin Coverage;Elan-Biogen Deal for Tysabri Violated

Biotechnology Law Report

Open accessResearch articleFirst published 2021

No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score–matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)

Helmut Butzkueven, Ludwig Kappos, Tim Spelman [...]

Therapeutic Advances in Neurological Disorders

Restricted accessOtherFirst published November, 2009

Severe relapses after the first infusion of natalizumab in active relapsing—remitting multiple sclerosis

Francesca Rinaldi, Paola Perini, Massimiliano Calabrese [...]

Multiple Sclerosis Journal

Open accessResearch articleFirst published 2019

The societal impact of treatment with natalizumab of relapsing–remitting multiple sclerosis in Italian clinical practice: The Tysabri ® PharmacoEconomics (TyPE) Study

B Polistena, F Spandonaro, R Capra [...]

Global & Regional Health Technology Assessment: Italian;Northern Europe and Spanish

Restricted accessResearch articleFirst published July, 2014

Smokers run increased risk of developing anti-natalizumab antibodies

AK Hedström, L Alfredsson, M Lundkvist Ryner [...]

Multiple Sclerosis Journal

Restricted accessResearch articleFirst published September, 2008

Early relapses after the first dose of natalizumab in active multiple sclerosis patients

D Centonze, R Furlan, C Gasperini [...]

Multiple Sclerosis Journal

Restricted accessOtherFirst published August, 2011

EMA Approves Revision of Label for Tysabri

Biotechnology Law Report

Restricted accessResearch articleFirst published February, 2011

An approach to natalizumab hypersensitivity: a case series of induction of tolerance

Marie Camacho-Halili, Roxanne George, Malcolm Gottesman [...]

Multiple Sclerosis Journal

Restricted accessResearch articleFirst published April, 2021

Real-world disability improvement in patients with relapsing–remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program

Heinz Wiendl, Tim Spelman, Helmut Butzkueven [...]

Multiple Sclerosis Journal

Restricted accessResearch articleFirst published March, 2021

Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri ® Observational Program (TOP)

Helmut Butzkueven, Maria Trojano, Ludwig Kappos [...]

Multiple Sclerosis Journal

Restricted accessOtherFirst published October, 2009

Medicare Taking Close Look at Erythropoietin Coverage;Elan-Biogen Deal for Tysabri Violated

Biotechnology Law Report

Open accessResearch articleFirst published 2021

No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score–matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)

Helmut Butzkueven, Ludwig Kappos, Tim Spelman [...]

Therapeutic Advances in Neurological Disorders

Restricted accessOtherFirst published November, 2009

Severe relapses after the first infusion of natalizumab in active relapsing—remitting multiple sclerosis

Francesca Rinaldi, Paola Perini, Massimiliano Calabrese [...]

Multiple Sclerosis Journal

Open accessResearch articleFirst published 2019

The societal impact of treatment with natalizumab of relapsing–remitting multiple sclerosis in Italian clinical practice: The Tysabri ® PharmacoEconomics (TyPE) Study

B Polistena, F Spandonaro, R Capra [...]

Global & Regional Health Technology Assessment: Italian;Northern Europe and Spanish

Restricted accessResearch articleFirst published July, 2014

Smokers run increased risk of developing anti-natalizumab antibodies

AK Hedström, L Alfredsson, M Lundkvist Ryner [...]

Multiple Sclerosis Journal

Restricted accessResearch articleFirst published September, 2008

Early relapses after the first dose of natalizumab in active multiple sclerosis patients

D Centonze, R Furlan, C Gasperini [...]

Multiple Sclerosis Journal